Skip to main content

RINVOQ (Abbvie Pty Ltd)

Product name
RINVOQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
222 working days (255)
Active ingredients
upadacitinib hemihydrate
Registration type
NCE/NBE
Indication

RINVOQ (modified release tablet) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).

RINVOQ may be used as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).

Help us improve the Therapeutic Goods Administration site